View more job listings or post a job
Hangzhou Zenshine Pharmaceuticals Director/Senior Director, Oncology
Genentech Scientific Researcher / Senior Scientific Researcher, Drug Metabolism And Pharmacokinetics
Hughes and Associates Senior Scientist Large Molecule Bioanalysis
Hughes and Associates Associate Director DMPK
Hughes and Associates Associate Director, Clinical Pharmacology and Pharmacometrics
Hughes and Associates Senior Director Clinical Pharmacology
Genentech Scientist–Drug Metabolism (Contract 2)
Genentech Scientist–Drug Metabolism (Contract 1)  
Drug Delivery Experts Associate Scientist
Post a job


Antibody Drug Conjugates: Chemistry, Biology, Pharmacokinetics and Toxicology

Speakers: Jagath Junutula (Cellerant), Andy Polson (Genentech) , Toni Kline (Sutro), Chetana Rao (BMS), Donglu Zhang (Genentech), Keyang Xu, PhD (Genentech), Melissa Schutten (Genentech)
Organizers: Thomas Pillow (Genentech)
Date: 9/12/2018
Time: 8:45-16:00
Registration fee (USD): Regular: $195; For unemployed or students: $30; Academic: $125; For major-sponsor rep (incl lunch): $0; For vendor-show rep: $35;
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (2)Applied BioMath, LLC; Intertek
Vendor show vendors registered to date: (24)Alturas Analytics; Applied StemCell, Inc.; Averica Discovery Services; BioPharmEquip; Bruker; CMIC, Inc.; JOINN Labs; KCAS Bioanalytical & Biomarker Services; MabPlex; Medpace; MicroConstants; Pacific BioLabs; PHARMout Laboratories; Promega; Q2 Solutions; QPS; SCIEX; Sekisui XenoTech, LLC; Selvita Inc.; Sepax Technologies; Shimadzu Scientific Instruments, Inc; Sigma Aldrich; SRI International; WuXi AppTec
Registration deadline:9/11/2018  (it will close sooner if the seating cap is reached)

About the Topic

Linking a small-molecule cytotoxic drug to a monoclonal antibody takes the strengths of both while potentially mitigating the liabilities. The resulting bioconjugates, known as antibody−drug conjugates or ADCs, have been validated clinically, with four approved anti-cancer agents for solid and hematological cancers. This workshop will broadly discuss the strategies for designing, constructing and analyzing ADCs utilizing the latest advances in the field.

This workshop will cover the following specific topics:

  • Overview of antibody-drug conjugates (ADCs) and clinical progress
  • Selecting a target for ADCs
  • The chemistry of linkers and drugs
  • Site-specific conjugation
  • Analytical characterization of ADCs
  • ADC bioanalysis & pharmacokinetics
  • Preclinical safety/toxicology

Workshop Agenda: 

Time Topic  Presenter
8:45-9:00 Welcome and Introduction Thomas Pillow
9:00-9:45 1. ADC Discovery & Development Jagath Junutula
9:45-10:30 2. ADCs for Hematological Malignancies Andy Polson
10:30-10:45 Break  
10:45-11:30 3. Conjugation Modalities for ADC Generation Chetana Rao
11:30-12:30 Lunch  
12:30-1:15 4. ADC Chemistry Toni Kline
1:15-2:00 5. Small Molecule DMPK for ADCs Donglu Zhang
2:00-2:15 Break  
2:15-3:00 6. Bioanalysis of ADCs   Keyang Xu
3:00-3:45 7. ADC Safety/Toxicity Melissa Schutten
3:45-4:15 Panel Discussion All
4:15-4:30 Final Remarks Thomas Pillow


2019-01-18, Fluorescence Imaging for the da Vinci Robotic Surgery Platform
2019-02-07, Covalent Inhibitor Drug Discovery & Development: Biology, Chemistry, PK, Safety and Case Studies (Jointly with Bay Area PKPD Network)
2019-03-07, Promising therapeutic approaches and transnational medicine from SPARK: an academic-industry collaboration to advance novel therapeutics (A Joint Symposium by PBSS and Stanford SPARK Program)
2019-03-11, Clinical Trials Essentials: An Intensive One-Week Course (register for the full week or half day sessions)
┬ęPharmaceutical & BioScience Society, International; Last Modified: 12/18/2018; Visited: 470; Admin Logon
Ads (in random order)
Submit a Text Ad
($200 for 2 months)